Abstract. The current study aimed to identify differentially expressed B cell-associated genes in peripheral blood mononuclear cells and observe the changes in B cell activation at different stages of coronary artery disease. Groups of patients with acute myocardial infarction (AMI) and stable angina (SA), as well as healthy volunteers, were recruited into the study (n=20 per group). Whole human genome microarray analysis was performed to examine the expression of B cell-associated genes among these three groups. The mRNA expression levels of 60 genes associated with B cell activity and regulation were measured using reverse transcription-quantitative polymerase chain reaction. The mRNA expression of the B cell antigen receptor (BCR)-associated genes, CD45, NFAM, SYK and LYN, were significantly upregulated in patients with AMI; however, FCRL3, CD79B, CD19, CD81, FYN, BLK, CD22 and CD5 mRNA expression levels were significantly downregulated, compared with patients in the SA and control group. The mRNA levels of the T-independent B cell-associated genes, CD16, CD32, LILRA1 and TLR9, were significantly increased in AMI patients compared with SA and control patients. The mRNA expression of genes associated with T-dependent B cells were also measured: EMR2 and CD97 were statistically upregulated, whereas SLAMF1, LY9, CD28, CD43, CD72, ICOSL, PD1, CD40 and CD20 mRNAs were significantly downregulated in AMI group patients compared with the two other groups. Additionally the gene expression levels of B cell regulatory genes were measured. In patients with AMI, CR1, LILRB2, LILRB3 and VAV1 mRNA expression levels were statistically increased, whereas, CS1 and IL4I1 mRNAs were significantly reduced compared with the SA and control groups. There was no statistically significant difference in B cell-associated gene expression levels between patients with SA and the control group. The present study identified the downregulation of genes associated with BCRs, B2 cells and B cell regulators in patients with AMI, indicating a weakened T cell-B cell interaction and reduced B2 cell activation during AMI. Thus, improving B2 cell-mediated humoral immunity may be a potential target for medical intervention in patients with AMI.
Introduction
Atherosclerosis is a major cause of coronary artery disease, which is a leading cause of mortality in numerous countries (1) . The presence of B lymphocytes during inflammatory infiltration in humans (2, 3) and mouse models (4, 5) has led to the investigation of their importance in atherosclerosis. However, the association between B cells and atherogenesis remains controversial. T-independent B cells (B1 cells) have atheroprotective properties (6, 7) , whereas T-dependent B cells (B2 cells) exhibit pro-atherogenic activity (8, 9) . The activation of B cells requires two signals. The first signal is the binding of an antigen to the B cell antigen receptor (BCR) expressed on the surface of B cells. If the antigen is thymus-independent, B cells can stimulate the second signal directly. However, thymus-dependent antigens require an interaction between T cells and B cells for the second signal to be initiated (10) . B1 and B2 cells constitute the two predominant B cell types, and are considered to be part of the innate and adaptive immune systems, respectively (11) . B1 cells are a minor group of B cells that produce natural antibodies against common microbial epitopes and self-determinants. By contrast, B2 cells are considered to be the conventional B lymphocytes, requiring signals from T helper cells to recognize specific antigens, and to produce and regulate antibody-mediated humoral immunity (12, 13) .
In the present study, the expression levels of a range of B cell-associated genes involved in B cell activation were examined. Human cDNA microarray analysis was used to detect the variations in gene expression levels at different stages of B cell activation and in subsets of peripheral blood mononuclear cells (PBMCs) isolated from patients with AMI and stable angina (SA), as well as healthy controls. The in vitro study was designed to investigate differential gene expression levels in B cells, and analyze the differences in humoral immunity in patients with AMI and SA.
Patients and methods
Patient information. The current study consisted of 3 groups of subjects: 20 patients with AMI, 20 patients with SA and 20 healthy volunteers. The baseline demographic data are presented in Table I . The patients with AMI were admitted to a Coronary Care Unit of Tongji Hospital (Shanghai, China), <12 h after the onset of symptoms between January and June 2013. The AMI group included 18 male and 2 female patients aged 58±12 years [mean ± standard deviation (SD)]. All patients with AMI were diagnosed on the basis of previously described criteria (14) . Briefly, selected subjects exhibited a rise in cardiac biomarker parameters (preferably cardiac troponin) with at least one value above the 99th percentile reference limit and with at least one of the following features: i) Symptoms of ischemia; ii) new or presumed new significant ST-segment-T wave changes or new left bundle branch block; iii) development of pathological Q waves in the electrocardiograph; iv) imaging evidence of new loss of viable myocardium or new regional wall motion abnormality; and v) identification of an intracoronary thrombus by angiography.
In the SA group, 18 male and 2 female patients of age 64±10 years (mean ± SD) with exclusively effort-associated angina were analyzed. Each patient exhibited positive exercise stress test results and at least one coronary stenosis was detected during angiography (>70% reduction of lumen diameter). There was no significant difference between AMI and SA patients (Table I) regarding age, gender, smoking status, body mass index, systolic blood pressure, diastolic blood pressure, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides or fasting glucose.
The control group consisted of 17 male and 3 female healthy volunteers of age 29±3 years (mean ± SD), recruited during the same time period as patients with AMI and SA. Family histories, physical examination, electrocardiograph, chest radiography and routine chemical analysis demonstrated that the controls had no evidence of coronary heart disease.
SA group candidates were outpatients with risk factors of cardiovascular disease and verified by electrocardiogram, cardio angiography or treadmill exercise test. The control candidates were individuals living in nearby communities without any risk factors or history of cardiovascular diseases. The exclusion criteria for the three groups were venous thrombosis, hematological disorders, acute or chronic inflammatory diseases, intake of hormones or immunosuppressors and malignancy.
The study protocol was approved by the ethics committee of Tongji University (Shanghai, China) and informed consent forms were obtained. Total RNA isolation. Peripheral blood samples (5 ml) were collected from patients with AMI and SA in PAXgene tubes (BD Biosciences, San Jose, CA, USA) immediately after admission. The control group blood samples were collected from nearby communities during the same period as AMI/SA blood collection in the hospital. Briefly, the leukocytes were isolated through density gradient centrifugation with Ficoll solution (Sigma Aldrich, St. Louis, MO, USA) and the remaining red blood cells were destroyed with erythrocyte lysis buffer (Qiagen GmbH, Hilden, Germany). Total RNA was extracted and purified using a PAXgene Blood RNA kit (cat no. 762174; Qiagen GmbH), according to the manufacturer's protocol. RNA integrity number (RIN) was measured to analyze RNA integration using an Agilent Bioanalyzer 2100 (Agilent Technologies, Inc.). Samples were considered to be high quality when RIN was ≥7.0 and 28S/18S was ≥1.7.
RNA amplification and labeling. Total RNA was amplified and labeled with Cy3 using a by Low Input Quick Amp Labeling kit, one-color (cat no. 5190-2305; Agilent Technologies, Inc.) according to the manufacturer's protocol. Labeled cRNA was purified using an RNeasy Mini kit (cat no. 74106, Qiagen GmbH).
Microarray hybridization. Each microarray slide was hybridized with 1.65 µg Cy3-labeled cRNA using a Gene Expression Hybridization kit (cat no. 5188-5242) in a hybridization oven (cat no. G2545A) at 37˚C, both purchased from Agilent Technologies, Inc., according to the manufacturer's protocol. After 17 h of hybridization, the slides were washed in staining dishes (cat no. 121; Thermo Fisher Scientific, Inc., Waltham, MA, USA) with a Gene Expression Wash Buffer kit (cat no. 5188-5327; Agilent Technologies, Inc.), according to the manufacturer's protocol.
Microarray scanning and data acquisition. The microarray slides were scanned with an Agilent Microarray Scanner (cat no. G2565CA; Agilent Technologies, Inc.) using the default settings (dye channel, green; scan resolution, 3 µm; 20 bit). Data were extracted using Feature Extraction software (version 10.7; Agilent Technologies, Inc.). Raw data were normalized using the Quantile algorithm function of Gene Spring software (version 11.0; Agilent Technologies, Inc.).
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
The spots on the microarray were randomly selected and their mRNA expression levels were confirmed by RT-qPCR. Briefly, reverse transcription was performed using the iScript reverse transcription supermix kit (Bio-Rad Laboratories, Inc., Hercules, CA, USA; cat. no. 1708841). The Ambion TURBO DNA-free DNase treatment kit (Thermo Fisher Scientific, Inc., Waltham, MA, USA; cat. no. AM1907) was utilized to remove contaminating DNA from RNA preparations according to the manufacturer's instructions. Real-time PCR was performed on a CFX96 Touch Real-time PCR detection system (Bio-Rad Laboratories, Inc.; cat. no. 1855195) using the iQ SYBR Green Supermix, (Bio-Rad Laboratories, Inc.; cat. no. 1708880) according to the manufacturer's instructions. The cycling conditions for RT-qPCR were as follows: 95˚C for 30 sec, 95˚C for 5 sec, 60˚C for 5 sec and plate read, 40 cycles at 95˚C for 30 sec, melting curve at 65-95˚C, increment 0.5˚C for 5 sec and plate read. Of the genes with differential expression levels, three were randomly selected, and these genes and a reference gene (GAPDH) were subjected to RT-qPCR. The relative expression levels were indicated as the expression of the target genes normalized to the expression of GAPDH (2 -ΔΔCq ). The melting curve and the 2 -ΔΔCq method (15) were used to detect differences in gene expression levels among the three groups. The results from RT-qPCR were consistent with the microarray analysis (data not shown).
Statistical analysis.
Values are expressed as the mean ± SD. A one-way analysis of variance (ANOVA) was used to examine differences between the groups. Pair-wise group comparisons following ANOVA were performed using Tukey's multiple comparison tests. Data were analyzed using SPSS version 17.0 (SPSS, Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference.
Results

mRNA expression levels of genes associated with BCR.
The present study measured the expression levels of 22 genes associated with the BCR in patients with AMI and SA, as well as controls subjects (Table II; Fig. 1 ). In PBMCs from the three groups, the expression levels of 15 genes were statistically different (P<0.05): CD45, NFAM1, BTK, SYK, LYN, FCRL3, CD79A, CD79B, CD19, CD21, CD81, FYN, BLK, CD22 and CD5. Compared with the control subjects, the gene expression levels of CD45, NFAM1, BTK, SYK, and LYN were significantly upregulated (P<0.05), whereas CD79A, CD21 (P<0.05), FCRL3, CD79B, CD19, CD81, FYN, BLK, CD22 and CD5 (P<0.01) mRNA expression were downregulated in the AMI group. In PBMCs from AMI patients, the expression of CD45, NFAM1, SYN and LYN were statistically increased (P<0.01), whereas FCRL3, CD79B, CD19, CD81, FYN, BLK, CD22 and CD5 expression were significantly reduced (P<0.05) compared with the levels in PBMCs from the SA group. There were no significant differences in BCR-associated mRNA expression levels between the SA and control group.
mRNA expression levels of genes associated with B1 cells.
The present study measured the expression levels of 7 genes associated with B1 cell activation in PBMCs from the AMI, SA and control groups (Table III; Fig. 2 ). In separate comparisons, CD16, CD32, LILRA1 and TLR9 mRNA levels were significantly increased in patients with AMI compared with SA and control patients (P<0.05). There was no statistical difference in the expression levels of genes associated with T1 cell activation between patients with SA and the control group.
mRNA expression levels of genes associated with B2 cells. The expression levels of 20 genes associated with B2 cell activation were examined in PBMCs from patients with AMI and SA, as well as control subjects (Table IV; Fig. 3 ). In PBMCs from the three groups, the expression levels of the following 11 genes were statistically different (P<0.05): EMR2, CD97, SLAMF1, LY9, CD28, CD43, CD72, ICOSL, PD1, CD40 and CD20. The mRNA expression levels of EMR2 and CD97 were significantly upregulated (P<0.01), whereas SLAMF1, LY9, CD28, CD43, CD72, ICOSL, PD1, CD40 and CD20 mRNAs were significantly downregulated (P<0.05), in the AMI group Table I . Baseline demographic data in AMI, SA and control groups. compared with the SA and control groups. There was no significant difference in the mRNA expression levels of genes associated with B2 cell activation between the SA and control groups.
mRNA expression levels of regulatory genes associated with B cell activation. In PBMCs from the AMI, SA and control groups, the expression levels of 11 regulatory genes associated with B cell activation were examined (Table V;   Table II . Expression of genes associated with B cell antigen receptor in B cell activation.
Gene expression In patients with AMI, the expression levels of LILRB1, LILRA3 (P<0.05), CR1, LILRB2, LILRB3 and VAV1 (P<0.01) were significantly increased, whereas the expression of CS1 and IL4I1 were significantly reduced (P<0.05), compared with the levels in the control group. When compared with the SA group patients, the mRNA levels of CR1, LILRB2, LILRB3 and VAV1 were significantly upregulated in patients with AMI (P<0.01), while CS1 and IL4I1 mRNAs were significantly downregulated (P<0.05). There were no significant differences in the gene expression levels of regulators of B cell activation between patients with SA and control subjects.
Discussion
The BCR is composed of a membrane-bound immunoglobulin (Ig) sheathed by an Igα/Igβ heterodimer. The receptor is critical in mediating the development and activation of B cells (16) . Ig recognizes antigens, and the induced signals are transmitted by Igα (CD79A) and Igβ. It was previously reported that high CD45 expression may reduce the expression of the BAFF and inhibit B cell survival (17, 18) . Furthermore, in vivo studies in mice indicated that overexpression of NFAM1 may severely impair early B cell development (19, 20) . LYN and FCRL3 appear to mediate positive and negative signaling during B cell activation (21, 22) , with a genetic ablation study indicating that LYN has an important inhibitory role in B cell signaling (23) . In addition, CD19, CD21, CD81 and FYN are B cell co-receptors that enhance BCR signal transduction (24) (25) (26) . By contrast, the B cell specific Src-family kinase, BLK, and CD5, which specifically bind the ligand of B cell surface Ig, are dispensable during B cell development and activation (27, 28) . In patients with AMI, the expression levels of CD45, NFAM1 and LYN were significantly increased, while CD79A, CD79B, CD19, CD21, CD81, FYN, BLK and CD5 were significantly decreased compared with the control group (Fig. 1) . The results of the current study indicate that the expression of mRNAs associated with BCR signals were downregulated in patients with AMI, possibly leading to inhibition of B cell activation and development. A comparison between SA patients and the control group demonstrated no significant difference in the mRNA levels of genes involved in BCR antigen recognition, which indicates that there may be differential BCR antigen recognition activity in patients with AMI and SA.
B1 cells are considered to function in the innate response to infection by viruses and bacteria, and typically demonstrate preferential responses to T cell-independent antigens (10, 12) . Among the 7 B1 cell-associated genes investigated, the expression levels of CD16, CD32, LILRA1 and TLR9 mRNAs were significantly upregulated in PBMCs from AMI patients compared with the SA and control groups (Fig. 2) . Previous studies have demonstrated that Fc γ receptors CD16 and CD32 may influence the growth and differentiation of B cells (29, 30) . LILRA1 mRNA transcripts were detected in B cells and the LILRA1 protein has been observed to activate cells by associating with the γ chain of Fc γ receptors (31, 32) . Furthermore, previous studies demonstrated that human B cells were activated by a TLR9 agonist (33, 34) . It was therefore proposed that Table III . Expression of genes associated with T-independent B cell activation. B1 cell activation is enhanced in patients with AMI, suggesting that an innate-like immune response occurs in AMI. However, there was no significant difference in B1 cell-associated gene expression between the SA patients and the control group. Thus, the results suggest that B1 cell activity is different in AMI and SA. B2 cells are important in B cell-specific humoral immunity (35) . Among the 20 genes examined, the mRNA expression levels of EMR2 and CD97 were significantly upregulated in AMI patients compared with the SA and control groups (Fig. 3) . EMR2 and CD97 are important for the interaction between T cells and B cells (36) . The SLAM family, including SLAMF1 and LY9, together with CD28 and CD43, are essential in the development and maturation of B cells, and the control of the humoral immune response (37) (38) (39) . The ICOS-ICOSL and PD1-PDL pathways are important for the stimulation of effector T cell and B2 cell responses (40) (41) (42) . The association between CD40 and CD40L, which are expressed on the surface of activated T cells, promotes the activation of B cells (43) . CD20 is a B cell-specific integral membrane protein that regulates B cell proliferation (44) . In the present study, the levels of SLAMF1, LY9, CD28, CD43, ICOSL, PD1, CD40 and CD20 mRNAs were lower in AMI patients compared with the control group (Fig. 3 ). These results demonstrate that the T cell-B cell interaction was weakened during the B2 cell activation in AMI. No significant differences were observed between the SA and control group patients, indicating that the potential insufficiency of the humoral response only occurred in the B2 subset during AMI.
Gene expression
Among the 11 regulatory genes associated with B cell activation examined, the mRNA expression levels of CR1, LILRB2, LILRB3, LILRA3 and VAV1 were significantly increased in AMI patients compared with those in the SA and control groups (Fig. 4) . CR1 is an inhibitor of BCR-mediated B cell activation (45) and LILRB negatively regulates the activation of antigen presenting cells (46, 47) . Additionally, it Gene ID  AMI  SA  Control has been previously demonstrated that mice lacking VAV1 exhibit defects in B cell activation (48) . Previous studies also observed that CS1 promotes the proliferation of human B lymphocytes and increases the expression of autocrine cytokines (20, (49) (50) (51) . Thus, the results of the current study indicate that B cell activation is inhibited in patients with AMI. Furthermore, there was no significant difference in the mRNA levels of genes associated with B cell activation between the SA and control groups. During the current study, standard gene testing procedures and appropriate statistical analyses were performed using randomly selected patients and controls, however, the study was not without limitations. Notably, there was an age difference between patients with AMI/SA and the control subjects. It is unclear whether aging affected the humoral response or whether the young control group had a normal immunity status compared with AMI/SA patients. However, the current data indicates that there was no significant difference in humoral immunity between patients with SA and the control group. The second limitation was the enhanced B1 cell activation observed in patients with AMI. B1 cells are a minor component of the total B cell population, which is a part of the innate immune response and produces natural antibodies. Thus, further in vitro studies are required to elucidate the pathological mechanisms of antigen processing pathways in the B cell system.
----------------------------------------------------------------
In conclusion, the statistical downregulation of genes associated with the BCR, B2 cells and B cell regulators in patients with AMI indicates that there is a weakened T cell-B cell interaction, as well as reduced B2 cell activation and development, during AMI. Notably, there were no statistical differences in the expression levels of B cell-associated genes between the SA and control groups, demonstrating that B2 cell dysfunction is only observable in AMI and not in SA. B2 cells are considered to be the conventional B lymphocytes, producing and regulating the antibody-mediated humoral immunity (12, 13) . Consequently, improving B2 cell-mediated humoral immunity may be considered as a potential target for the treatment of patients with AMI.
